A detailed history of Daiwa Securities Group Inc. transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Daiwa Securities Group Inc. holds 239 shares of SAGE stock, worth $1,283. This represents 0.0% of its overall portfolio holdings.

Number of Shares
239
Previous 239 -0.0%
Holding current value
$1,283
Previous $3,000 33.33%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 06, 2023

BUY
$32.2 - $43.61 $611 - $828
19 Added 8.64%
239 $9,000
Q2 2022

Aug 09, 2022

BUY
$27.52 - $37.99 $1,320 - $1,823
48 Added 27.91%
220 $7,000
Q4 2021

Feb 03, 2022

SELL
$37.06 - $47.11 $1,074 - $1,366
-29 Reduced 14.43%
172 $7,000
Q3 2021

Nov 05, 2021

BUY
$40.26 - $57.37 $3,422 - $4,876
85 Added 73.28%
201 $9,000
Q1 2021

May 03, 2021

BUY
$70.65 - $96.76 $1,271 - $1,741
18 Added 18.37%
116 $9,000
Q4 2020

Feb 04, 2021

SELL
$58.41 - $89.06 $11,331 - $17,277
-194 Reduced 66.44%
98 $8,000
Q1 2020

May 14, 2020

SELL
$26.15 - $77.24 $89,720 - $265,010
-3,431 Reduced 92.16%
292 $8,000
Q4 2019

Jan 31, 2020

BUY
$60.18 - $154.77 $19,137 - $49,216
318 Added 9.34%
3,723 $269,000
Q3 2019

Nov 04, 2019

SELL
$140.29 - $189.96 $44,892 - $60,787
-320 Reduced 8.59%
3,405 $478,000
Q2 2019

Jul 24, 2019

SELL
$157.85 - $183.09 $89,343 - $103,628
-566 Reduced 13.19%
3,725 $682,000
Q1 2019

Apr 26, 2019

BUY
$89.33 - $163.65 $355,622 - $651,490
3,981 Added 1284.19%
4,291 $683,000
Q4 2018

Feb 05, 2019

BUY
$81.94 - $139.71 $6,555 - $11,176
80 Added 34.78%
310 $30,000
Q1 2018

May 02, 2018

BUY
$152.15 - $192.33 $34,994 - $44,235
230 New
230 $37,000

Others Institutions Holding SAGE

About Sage Therapeutics, Inc.


  • Ticker SAGE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,422,300
  • Market Cap $319M
  • Description
  • Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...
More about SAGE
Track This Portfolio

Track Daiwa Securities Group Inc. Portfolio

Follow Daiwa Securities Group Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Daiwa Securities Group Inc., based on Form 13F filings with the SEC.

News

Stay updated on Daiwa Securities Group Inc. with notifications on news.